NCT04883125View on ClinicalTrials.gov

Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

April 15, 2021

Study Completion Date

April 15, 2021

Conditions
Chronic Myelogenous Leukemia, BCR-ABL PositiveCML, Chronic Phase
Interventions
DRUG

Pioglitazone 15mg

pioglitazone (7.5-30 mg) once daily plus imatinib 400 mg 6 months

Trial Locations (1)

35511

Faculty of Medicine, Al Mansurah

All Listed Sponsors
lead

Mansoura University

OTHER

NCT04883125 - Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment | Biotech Hunter | Biotech Hunter